Ex­clu­sive: With back­ing of Ravens own­er, Black­bird launch­es with $100M to boost Bal­ti­more’s biotech scene

Last year
Financing
Startups

Dutch-US biotech rais­es $61M to test ex-Mit­subishi Tan­abe drug for schiz­o­phre­nia

Last year
Financing
Startups

Ver­tex dis­con­tin­ues a PhII rare dis­ease drug, sets ear­ly 2024 time­line for piv­otal non-opi­oid pain pill read­out

Last year
R&D
Pharma

'Pull every lev­er': Marks dou­bles down on ur­gency to im­prove gene ther­a­py man­u­fac­tur­ing

Last year
Pharma
Cell/Gene Tx

Bris­tol My­er­s' new ef­fort spot­lights pso­ri­a­sis pa­tients and physi­cians from around the world

Last year
Pharma
Marketing

Court may ex­pand 340B drug dis­count pro­gram as CMS preps $9B for 1,700 hos­pi­tals

Last year
Pharma
Law

HHS says Ste­lara may be de­s­e­lect­ed from Medicare ne­go­ti­a­tions, de­pend­ing on biosim­i­lar launch

Last year
Pharma
FDA+

Ko­di­ak 're­boot­s' Eylea com­peti­tor af­ter pos­i­tive da­ta in di­a­bet­ic vi­sion loss tri­al

Last year
R&D

Moon­Lake’s stock falls more than 20% de­spite mid-stage suc­cess in pso­ri­at­ic arthri­tis

Last year
R&D

Zen­tal­is shakes up PhI­II plans in ovar­i­an can­cer; Halozyme's deal with Acu­men; Ko­r­ro's $117M pri­vate place­ment

Last year
News Briefing

CAR­GO Ther­a­peu­tics eyes one of 2023's largest IPOs in a dull year for list­ings

Last year
Financing
Startups

Up­dat­ed: Cel­lares to pro­duce Ca­balet­ta’s au­toim­mune CAR-T can­di­date 

Last year
Deals
Manufacturing

The End­points Slack in­ter­view: Roivant CEO Matt Gline on play­ing mon­ey­ball in phar­ma, Vivek and pol­i­tics, and the $7B ...

Last year
People

BioN­Tech grabs PD-L1/VEGF bis­pe­cif­ic with $55M up­front, ex­pand­ing pipeline while low­er­ing Covid guid­ance

Last year
Deals
China

RAPT Ther­a­peu­tics bol­sters part­ner search with PhII da­ta on small mol­e­cule-Keytru­da com­bo

Last year
R&D

As­traZeneca, Ele­don and Alpine spell out kid­ney pro­gram suc­cess­es: ASN roundup

Last year
R&D

Bris­tol My­ers buys Orum Ther­a­peu­tic­s' pro­tein de­grad­er take on AD­Cs for $100M up­front

Last year
Startups
Deals

Star­ton Ther­a­peu­tics scraps SPAC deal that would have tak­en it pub­lic, brought in $50M

Last year
Deals

Lat­est news on BioN­Tech's Fri­day buy­out; Un­pack­ing Sarep­ta’s Duchenne da­ta; Pfiz­er’s post-Covid plans; Eli Lil­ly, ...

Last year
Weekly

House Over­sight Com­mit­tee opens probe in­to FDA's han­dling of drug short­ages

Last year
FDA+
Manufacturing

BIO, PhRMA press FDA for con­crete de­tails on new IT strat­e­gy

Last year
Pharma
FDA+

FDA hands In­di­a's Nat­co Phar­ma an­oth­er 483, with eight ob­ser­va­tions cit­ed 

Last year
FDA+
Manufacturing

Ex­clu­sive: BioN­Tech ac­quires lipid nanopar­ti­cle start­up found­ed by George Ma­son and UPenn sci­en­tists

Last year
Deals

What's fair: ICER re­port finds in­sur­er cov­er­age typ­i­cal­ly meets ac­cess cri­te­ria for 18 pre­scrip­tion drugs

Last year
Pharma
First page Previous page 250251252253254255256 Next page Last page
A service from the Financial Times